Raj Chovatiya, MD: Key Ingredients in Moisturizers for Atopic Dermatitis

March 19, 2024

Dr. Chovatiya reviews the science behind moisturization in atopic dermatitis (AD), highlighting specific ingredients shown to support barrier repair and symptom control. His discussion focuses on how thoughtful moisturizer selection can complement prescription therapies and improve overall disease management.

Click here to read Dr. Chovatiya’s latest article in the February issue of The Journal of Clinical and Aesthetic Dermatology, where he explores the topic of moisturization for patients with AD.

Topics Covered:

The role of moisturizers in maintaining skin barrier integrity
Natural moisturizing factors (NMFs) and their impact on hydration
Glycerin as a humectant to attract and retain moisture
Ceramides and their importance in restoring barrier function
Practical guidance for recommending moisturizers to patients with AD

Explore Related Resources:

MORE EXPERT PERSPECTIVES IN ATOPIC DERMATITIS:

Raj Chovatiya, MD, PhD, MSCI: Advancements in Topical Therapy for Atopic Dermatitis

Raj Chovatiya, MD, PhD, MSCI, an associate professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and founder and director of the

David Seiter, FNP-C: Rapid Relief for Atopic Dermatitis Flares

David Seiter, FNP-C, shares a patient success story involving a teenage patient with severe atopic dermatitis that achieved complete skin clearance within one week after

Christopher Bunick, MD, PhD: Rapid Itch Relief with Upadacitinib vs. Dupilumab in Atopic Dermatitis

Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch

George Han, MD, PhD: Advancing Atopic Dermatitis Care: Early Use of Topical JAK Inhibitors

George Han, MD, PhD, discusses the evolving treatment strategies for patients with atopic dermatitis.

Kara Mudd DMSc, PA-C: Use of Ruxolitinib in Pediatric Patients with Atopic Dermatitis

Kara Mudd reviews findings from the Phase 3 TRuE-AD3 study evaluating topical ruxolitinib in children aged 2 to <12 years with atopic dermatitis. The discussion

Mona Shahriari, MD: Removal of Black Box Warnings Change Considerations for Hormonal Therapy in Atopic Dermatitis

Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment

Emma Guttman-Yassky, MD: Evaluating Long-term Efficacy of Upadacitinib in Patients with Atopic Dermatitis

Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP

Lisa Swanson, MD: Topical Therapies for the Treatment of Atopic Dermatitis

Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for

Raj Chovatiya, MD, PhD: Maintaining Optimal Treatment Targets with Upadacitinib for Patients with Atopic Dermatitis

Dr. Raj Chovatiya presents long-term data on upadacitinib’s ability to maintain skin clearance and itch relief in atopic dermatitis patients over 140 weeks. Topics Covered:

JCAD Archives